+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021

  • ID: 5305167
  • Drug Pipelines
  • March 2021
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Aclaris Therapeutics
  • Inflazome
  • Novartis
  • Roche
  • MORE
This “Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Cryopyrin-Associated Periodic Syndrome (CAPS) Understanding

Cryopyrin-Associated Periodic Syndrome (CAPS): Overview

Cryopyrin-associated periodic syndrome or syndromes (CAPS), also known as cryopyrinopathies, are genetic autoinflammatory syndromes defined by ‘gain-of-function' mutations affecting the cryopyrin protein. Cryopyrin-associated periodic syndromes are all autosomal dominant genetic conditions, meaning only one copy of the abnormal gene is required to develop the clinical syndrome. CAPS comprises 3 disorders on a continuum of severity: severe CINCA syndrome, intermediate Muckle-Wells syndrome (MWS) and milder familial cold urticaria (FCAS).

"Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape is provided which includes the disease overview and Cryopyrin-Associated Periodic Syndrome (CAPS) treatment guidelines. The assessment part of the report embraces, in depth Cryopyrin-Associated Periodic Syndrome (CAPS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cryopyrin-Associated Periodic Syndrome (CAPS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cryopyrin-Associated Periodic Syndrome (CAPS) R&D. The therapies under development are focused on novel approaches to treat/improve Cryopyrin-Associated Periodic Syndrome (CAPS).

Cryopyrin-Associated Periodic Syndrome (CAPS) Emerging Drugs Chapters

This segment of the Cryopyrin-Associated Periodic Syndrome (CAPS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cryopyrin-Associated Periodic Syndrome (CAPS) Emerging Drugs

ATI-450: Aclaris Therapeutics

ATI-450 is an oral small molecule MAPKAPK2 (MK2) inhibitor that potently inhibits multiple inflammatory cytokines. ATI-450, an investigational drug formerly known as CDD-450, is a unique p38α MAPK-MK2 pathway selective inhibitor used to uncover the function of this protein complex in inflammasome priming signals. The Drug is being evaluated in phase II stage of development for the treatment of Cryopyrin-Associated Periodic Syndrome. ATI-450's offers the potential lack of transient efficacy and safety issues associated with global p38α MAPK inhibitors.

IZD334: Inflazome

IZD334 is a NLRP3 protein inhibitors. Activated NLRP3 acts as a ‘danger sensor' in the body to release the pro-inflammatory cytokines IL-1β, IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases. Acquisition of Inflazome had gives Roche full rights to the Inflazome portfolio

Cryopyrin-Associated Periodic Syndrome (CAPS): Therapeutic Assessment

This segment of the report provides insights about the different Cryopyrin-Associated Periodic Syndrome (CAPS) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cryopyrin-Associated Periodic Syndrome (CAPS)

There are approx. 5+ key companies which are developing the therapies for Cryopyrin-Associated Periodic Syndrome (CAPS). The companies which have their Cryopyrin-Associated Periodic Syndrome (CAPS) drug candidates in the most advanced stage, i.e. phase II include, Aclaris Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
Route of Administration

Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular
Molecule Type

Products have been categorized under various Molecule types such as
  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cryopyrin-Associated Periodic Syndrome (CAPS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cryopyrin-Associated Periodic Syndrome (CAPS) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cryopyrin-Associated Periodic Syndrome (CAPS) drugs.

Cryopyrin-Associated Periodic Syndrome (CAPS) Report Insights
  • Cryopyrin-Associated Periodic Syndrome (CAPS) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Cryopyrin-Associated Periodic Syndrome (CAPS) Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Cryopyrin-Associated Periodic Syndrome (CAPS) drugs?
  • How many Cryopyrin-Associated Periodic Syndrome (CAPS) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cryopyrin-Associated Periodic Syndrome (CAPS) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cryopyrin-Associated Periodic Syndrome (CAPS) and their status?
  • What are the key designations that have been granted to the emerging drugs?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aclaris Therapeutics
  • Inflazome
  • Novartis
  • Roche
  • MORE
Introduction

Executive Summary

Cryopyrin-Associated Periodic Syndrome (CAPS): Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Cryopyrin-Associated Periodic Syndrome (CAPS) - Analytical Perspective

In-depth Commercial Assessment
  • Cryopyrin-Associated Periodic Syndrome (CAPS) companies' collaborations, Licensing, Acquisition -Deal Value Trends
Cryopyrin-Associated Periodic Syndrome (CAPS) Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
  • Comparative Analysis
ATI-450: Acaris therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Eraly Stage Products (Phase I)
  • Comparative Analysis
IZD453: Inflazome
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Companies

Cryopyrin-Associated Periodic Syndrome (CAPS) Key Products

Cryopyrin-Associated Periodic Syndrome (CAPS)- Unmet Needs

Cryopyrin-Associated Periodic Syndrome (CAPS)- Market Drivers and Barriers

Cryopyrin-Associated Periodic Syndrome (CAPS)- Future Perspectives and Conclusion

Cryopyrin-Associated Periodic Syndrome (CAPS) Analyst Views

Cryopyrin-Associated Periodic Syndrome (CAPS) Key Companies

Appendix

List of Tables
Table 1 Total Products for Cryopyrin-Associated Periodic Syndrome (CAPS)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Cryopyrin-Associated Periodic Syndrome (CAPS)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
3 of 3
  • Aclaris Therapeutics
  • Inflazome
  • Novartis
  • Roche
Note: Product cover images may vary from those shown
Adroll
adroll